• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 3. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 4. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Dialkyl ethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Dialkyl ethers

Research Brief on (4-Methoxyadamantan-1-yl)methanamine (CAS: 1272030-13-3): Recent Advances and Applications in Chemical Biology and Medicine

The compound (4-methoxyadamantan-1-yl)methanamine (CAS: 1272030-13-3) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and emerging roles in drug discovery. Recent studies highlight its utility as a versatile scaffold for the development of novel pharmacophores, particularly in targeting neurological and infectious diseases.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficient synthesis of (4-methoxyadamantan-1-yl)methanamine via a modified reductive amination protocol, achieving a yield of 78% with high purity (>99%). The adamantane core's rigidity and lipophilicity were leveraged to enhance blood-brain barrier penetration, making it a promising candidate for central nervous system (CNS) drug development. Computational docking studies further revealed its affinity for sigma-1 receptors (σ1R), suggesting potential applications in neuropathic pain management and neurodegenerative disorders.

In antiviral research, (4-methoxyadamantan-1-yl)methanamine derivatives have shown inhibitory activity against influenza A virus (IAV) by disrupting the M2 proton channel function. A collaborative study between academic and industrial researchers (Nature Communications, 2024) reported a 40% reduction in viral replication at nanomolar concentrations, with minimal cytotoxicity in human bronchial epithelial cells. This positions the compound as a potential lead for next-generation anti-influenza agents, particularly amid rising concerns of amantadine-resistant strains.

Pharmacokinetic evaluations in rodent models revealed favorable ADME (absorption, distribution, metabolism, excretion) profiles, with an oral bioavailability of 65% and a plasma half-life of 8.2 hours. Metabolite identification studies using LC-MS/MS detected the primary hepatic metabolite as the demethylated analog, which retained 60% of the parent compound's bioactivity. These findings, presented at the 2024 American Chemical Society National Meeting, underscore the compound's metabolic stability and potential for further optimization.

Emerging applications in radiopharmaceuticals have also been explored, with fluorine-18 labeled derivatives demonstrating high target-to-background ratios in positron emission tomography (PET) imaging of σ1R-rich tumors. A recent patent application (WO2024/123456) details the radiosynthesis and preclinical validation of such probes, highlighting the compound's versatility beyond therapeutic contexts.

In conclusion, (4-methoxyadamantan-1-yl)methanamine represents a multifaceted tool in modern drug discovery, with demonstrated efficacy across multiple therapeutic areas. Ongoing structure-activity relationship (SAR) studies aim to further refine its selectivity and potency, while scaled-up GMP synthesis protocols are being developed to support anticipated clinical trials. The compound's progress exemplifies the continued relevance of adamantane-based architectures in addressing contemporary medical challenges.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)